Brief: Spago Nanomedical Q4 Sales SEK 4 Thousand
05/02/2026 07:00
Feb 05 (Reuters) - Spago Nanomedical Q4 net income SEK -5.89 million. Q4 adjusted EPS SEK -0.01 Q4 operating expenses SEK -6.943 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose